91 related articles for article (PubMed ID: 20235353)
21. Triumph and tragedy: anemia management in chronic kidney disease.
Novak JE; Szczech LA
Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
[TBL] [Abstract][Full Text] [Related]
22. Anemia in renal disease: diagnosis and management.
Lankhorst CE; Wish JB
Blood Rev; 2010 Jan; 24(1):39-47. PubMed ID: 19833421
[TBL] [Abstract][Full Text] [Related]
23. Therapy with erythropoiesis-stimulating agents and renal and nonrenal outcomes.
Agarwal AK; Singh AK
Heart Fail Clin; 2010 Jul; 6(3):323-32. PubMed ID: 20630407
[TBL] [Abstract][Full Text] [Related]
24. Optimizing anemia management in hospitalized patients with end-stage renal disease.
Heung M; Mueller BA; Segal JH
Ann Pharmacother; 2009 Feb; 43(2):276-82. PubMed ID: 19141655
[TBL] [Abstract][Full Text] [Related]
25. [Regarding the optimal hemoglobin target range in renal anemia].
Maurin N
Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
[TBL] [Abstract][Full Text] [Related]
26. Erythropoiesis-stimulating agents and heart failure.
Lipšic E; van der Meer P; van Veldhuisen DJ
Cardiovasc Ther; 2011 Aug; 29(4):e52-9. PubMed ID: 20973926
[TBL] [Abstract][Full Text] [Related]
27. Emerging drugs for treatment of anemia of chronic kidney disease.
Magwood JS; Lebby A; Chen B; Kessler S; Norris L; Bennett CL
Expert Opin Emerg Drugs; 2013 Dec; 18(4):421-9. PubMed ID: 24033253
[TBL] [Abstract][Full Text] [Related]
28. Erythropoiesis stimulatory agent- resistant anemia in dialysis patients: review of causes and management.
Kanbay M; Perazella MA; Kasapoglu B; Koroglu M; Covic A
Blood Purif; 2010; 29(1):1-12. PubMed ID: 19816014
[TBL] [Abstract][Full Text] [Related]
29. The benefits of IV iron therapy in treating anemia in patients with renal disease and comorbid cardiovascular disease.
Singh AK; Hertello P
Nephrol Nurs J; 2005; 32(2):199-206; quiz 207-8. PubMed ID: 15889804
[TBL] [Abstract][Full Text] [Related]
30. The role of erythropoiesis-stimulating agents in the treatment of anemia.
Fishbane S
Am J Manag Care; 2010 Mar; 16 Suppl Issues():S67-73. PubMed ID: 20297874
[TBL] [Abstract][Full Text] [Related]
31. From anemia trials to clinical practice: understanding the risks and benefits when setting goals for therapy.
Coyne DW
Semin Dial; 2008; 21(3):212-6. PubMed ID: 18363603
[TBL] [Abstract][Full Text] [Related]
32. Is nephrology more at ease than oncology with erythropoiesis-stimulating agents? Treatment guidelines and an update on benefits and risks.
Locatelli F; Gascón P
Oncologist; 2009; 14 Suppl 1():57-62. PubMed ID: 19762517
[TBL] [Abstract][Full Text] [Related]
33. Anemia in renal insufficiency.
Santoro A
Rev Clin Exp Hematol; 2002; Suppl 1():12-20. PubMed ID: 12735211
[TBL] [Abstract][Full Text] [Related]
34. What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level?
Singh AK
Curr Opin Nephrol Hypertens; 2010 Sep; 19(5):420-4. PubMed ID: 20689425
[TBL] [Abstract][Full Text] [Related]
35. The treatment of anemia in chronic kidney disease: understandings in 2006.
Levin A
Curr Opin Nephrol Hypertens; 2007 May; 16(3):267-71. PubMed ID: 17420672
[TBL] [Abstract][Full Text] [Related]
36. ESA therapy - the quest continues: anemia treatment following recent national and international recommendations 2011 and 2012.
Biggar P; Ketteler M
Clin Nephrol; 2013 May; 79(5):335-50. PubMed ID: 23391317
[TBL] [Abstract][Full Text] [Related]
37. Update on anemia management in nephrology, including current guidelines on the use of erythropoiesis-stimulating agents and implications of the introduction of "biosimilars".
Locatelli F; Becker H
Oncologist; 2009; 14 Suppl 1():16-21. PubMed ID: 19762513
[TBL] [Abstract][Full Text] [Related]
38. An expert opinion on the current treatment of anemia in patients with kidney disease.
Locatelli F; Del Vecchio L
Expert Opin Pharmacother; 2012 Mar; 13(4):495-503. PubMed ID: 22296648
[TBL] [Abstract][Full Text] [Related]
39. Anemia management and chronic renal failure progression.
Rossert J; Froissart M; Jacquot C
Kidney Int Suppl; 2005 Dec; (99):S76-81. PubMed ID: 16336582
[TBL] [Abstract][Full Text] [Related]
40. Erythropoiesis-stimulating agents for the management of anemia of chronic kidney disease: past advancements and current innovations.
Dutka P
Nephrol Nurs J; 2012; 39(6):447-57. PubMed ID: 23469411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
